Review of teriflunomide and its potential in the treatment of multiple sclerosis
Clemens Warnke1, Gerd Meyer zu Hörste1, Hans-Peter Hartung1, Olaf Stüve2,3,4, Bernd C Kieseier11Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany; 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Dep...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2009
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fd84723399604573b06e092ab975204f |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:fd84723399604573b06e092ab975204f |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:fd84723399604573b06e092ab975204f2021-12-02T02:59:50ZReview of teriflunomide and its potential in the treatment of multiple sclerosis1176-63281178-2021https://doaj.org/article/fd84723399604573b06e092ab975204f2009-05-01T00:00:00Zhttp://www.dovepress.com/review-of-teriflunomide-and-its-potential-in-the-treatment-of-multiple-a3170https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Clemens Warnke1, Gerd Meyer zu Hörste1, Hans-Peter Hartung1, Olaf Stüve2,3,4, Bernd C Kieseier11Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany; 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Department of Neurology; 4Department of immunology, University of Texas Southwestern Medical Center at Dallas, TX, USAAbstract: In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.Keywords: teriflunomide, multiple sclerosis, immunosuppressant, oral drugs Clemens WarnkeGerd Meyer zu HörsteHans-Peter HartungOlaf Stüveet al.Dove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2009, Iss default, Pp 333-340 (2009) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Clemens Warnke Gerd Meyer zu Hörste Hans-Peter Hartung Olaf Stüve et al. Review of teriflunomide and its potential in the treatment of multiple sclerosis |
| description |
Clemens Warnke1, Gerd Meyer zu Hörste1, Hans-Peter Hartung1, Olaf Stüve2,3,4, Bernd C Kieseier11Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany; 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Department of Neurology; 4Department of immunology, University of Texas Southwestern Medical Center at Dallas, TX, USAAbstract: In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.Keywords: teriflunomide, multiple sclerosis, immunosuppressant, oral drugs |
| format |
article |
| author |
Clemens Warnke Gerd Meyer zu Hörste Hans-Peter Hartung Olaf Stüve et al. |
| author_facet |
Clemens Warnke Gerd Meyer zu Hörste Hans-Peter Hartung Olaf Stüve et al. |
| author_sort |
Clemens Warnke |
| title |
Review of teriflunomide and its potential in the treatment of multiple sclerosis |
| title_short |
Review of teriflunomide and its potential in the treatment of multiple sclerosis |
| title_full |
Review of teriflunomide and its potential in the treatment of multiple sclerosis |
| title_fullStr |
Review of teriflunomide and its potential in the treatment of multiple sclerosis |
| title_full_unstemmed |
Review of teriflunomide and its potential in the treatment of multiple sclerosis |
| title_sort |
review of teriflunomide and its potential in the treatment of multiple sclerosis |
| publisher |
Dove Medical Press |
| publishDate |
2009 |
| url |
https://doaj.org/article/fd84723399604573b06e092ab975204f |
| work_keys_str_mv |
AT clemenswarnke reviewofteriflunomideanditspotentialinthetreatmentofmultiplesclerosis AT gerdmeyerzuhampoumlrste reviewofteriflunomideanditspotentialinthetreatmentofmultiplesclerosis AT hanspeterhartung reviewofteriflunomideanditspotentialinthetreatmentofmultiplesclerosis AT olafstampuumlve reviewofteriflunomideanditspotentialinthetreatmentofmultiplesclerosis AT etal reviewofteriflunomideanditspotentialinthetreatmentofmultiplesclerosis |
| _version_ |
1718402019377545216 |